Belite Bio (BLTE) director details stock option grants and vesting
Rhea-AI Filing Summary
Belite Bio director Gary Clark Biddle filed an initial ownership report showing stock option holdings in the company. He holds options covering 50,000 ordinary shares at an exercise price of $6.00 per share, expiring on April 17, 2032. This option vests over three years: 20,000 shares vest in 12 equal monthly installments after April 28, 2022, and the remaining 30,000 vest in 24 monthly installments after the first anniversary of that date, all subject to continued service. He also holds options over 60,000 ordinary shares at an exercise price of $58.88 per share, expiring on April 14, 2035, which vest in 36 equal monthly installments after April 15, 2025, subject to continued service. The filing lists these option positions and vesting terms rather than reporting any share purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (right to buy) | -- | -- | -- |
| holding | Stock Option (right to buy) | -- | -- | -- |
Footnotes (1)
- The option shall vest (i) as to 20,000 ordinary shares subject to the option in 12 equal and continuous monthly installments for each full month of services completed following April 28, 2022, and (ii) as to the remaining 30,000 ordinary shares subject to the option in 24 equal and continuous monthly installments for each full month of services completed following the first anniversary of April 28, 2022, subject to continued service to the Issuer on each such date. The option shall vest as to 60,000 ordinary shares subject to the option in 36 equal and continue monthly installments for each full month of services completed following April 15, 2025, subject to continued service to the Issuer on such date.